Fredric P Manfredsson

Title: Fredric P Manfredsson: Innovator in Parkinson's Disease Treatment

Introduction

Fredric P Manfredsson is a notable inventor based in Grand Rapids, MI (US). He has made significant contributions to the field of medical research, particularly in the treatment of movement disorders associated with Parkinson's disease. His innovative approach focuses on the genetic target Nurr1, which plays a crucial role in managing levodopa-induced dyskinesias.

Latest Patents

Fredric holds a patent titled "Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease." This patent discloses methods for treating movement disorders by reducing the activity of Nurr1. These methods are particularly applicable to individuals suffering from Parkinson's disease who have developed levodopa-induced dyskinesia (LID) or are at risk of developing it. The invention outlines a method for treating a movement disorder by administering a therapeutically effective amount of a composition that reduces the activity of the nuclear receptor related 1 protein (Nurr1). In some embodiments, the movement disorder addressed is dyskinesia, specifically levodopa-induced dyskinesia.

Career Highlights

Fredric is affiliated with Michigan State University, where he continues to advance his research in the field of movement disorders. His work has garnered attention for its potential to improve the quality of life for individuals affected by Parkinson's disease.

Collaborations

Fredric collaborates with esteemed colleagues, including Timothy Collier and Kathy Steece-Collier, who contribute to his research endeavors and help further the understanding of movement disorders.

Conclusion

Fredric P Manfredsson's innovative work in targeting Nurr1 for the treatment of levodopa-induced dyskinesias represents a significant advancement in Parkinson's disease research. His contributions have the potential to transform treatment approaches and improve patient outcomes.